Nova IVF Fertility has announced the adoption of Artificial Intelligence (AI) in its IVF laboratories through Vita Embryo, an AI-based embryo assessment technology developed by South Korea’s Kai Health.
Shobhit Agarwal, CEO, Nova IVF Fertility (Source: prhandout)
The system is being rolled out across Nova’s 120 clinics in 65 cities, aimed at improving precision in embryo selection—one of the most critical factors in IVF success.
Traditionally, embryologists assess embryos based on experience and grading systems. With AI acting as an additional layer of evaluation, subtle indicators of embryo health that may be difficult to detect manually can now be identified. This is expected to enhance pregnancy rates, reduce the number of cycles required, and bring greater transparency to the treatment journey.
“With fertility rates declining in countries like India, 1 in 6 couples struggling to conceive, the need for precision in fertility treatment is the need of the hour… We believe that advanced technologies like this should be accessible to all patients in metros and tier 2 regions, without any additional monetary charges,” said Shobhit Agarwal, CEO, Nova IVF Fertility.
Dr. Hyejun Lee, CEO of Kai Health, added, “Our research indicates that with the intervention of AI, the precision of selecting embryos increased by 12%… We shall continue to focus on technological excellence and clinical impact by partnering with leading IVF networks globally.”
Empower your business. Get practical tips, market insights, and growth strategies delivered to your inbox
By continuing you agree to our Privacy Policy & Terms & Conditions
